WE@HealthTech
Ronit Berger serves as the Immuno-Oncology Brand Lead at Bristol Myers Squibb since June 2018, overseeing thoracic and GU malignancies and acting as the South East Asia Oncology Advisor. In previous roles, Ronit led commercial activities for top-selling immuno-oncology assets Opdivo and Yervoy while contributing to the company's business strategy. Additionally, Ronit has been involved with the Woman Executive Launchpad initiative at WE@HealthTech since April 2022 and worked as a Product Specialist in the Oncotest Diagnostic Division at Teva Pharmaceuticals from September 2006 until June 2018. Educational qualifications include a Bachelor's degree in Social Welfare and Health Sciences from the University of Haifa and ongoing studies at Reichman University.
This person is not in the org chart
WE@HealthTech
Women comprise about 70% of the HealthTech industry work force. Out of the 30 companies listed in the Biomed Index there are only two women CEOs amongst a total of sixty CEOs and Chairmen. The share value of companies that include women on their boards are higher by an average of 44% (Goldman Sachs). FORTUNE 500 companies with a larger number of women in senior management positions have better financial results (Catalyst). It follows that proper representation of women in top managerial levels will serve not only social and gender equality goals, but also organizational, business, and economic goals and performance. In partnership with 8400 we introduce a HealthTech launchpad program to promote junior women managers to executive positions throughout the ecosystem.